Black Diamond Therapeutics (BDTX) Assets Average (2020 - 2026)

Black Diamond Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $138.0 million for Q1 2026.

• Quarterly Assets Average fell 7.68% year-over-year to $138.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $138.0 million (down 7.68% YoY) and the FY2025 annual result came in at $132.8 million, down 5.53% from the prior year.
• Assets Average was $138.0 million for Q1 2026 at Black Diamond Therapeutics, down from $150.4 million in the prior quarter.
• Across five years, Assets Average topped out at $233.6 million in Q1 2022 and bottomed at $127.7 million in Q2 2023.
• A 5-year average of $160.5 million and a median of $150.4 million in 2025 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average plunged 38.93% — and 2025, when it advanced 17.14%.
• Black Diamond Therapeutics' Assets Average stood at $168.3 million in 2022, then slipped by 1.7% to $165.5 million in 2023, then dropped by 21.28% to $130.3 million in 2024, then rose by 15.43% to $150.4 million in 2025, then retreated by 8.25% to $138.0 million in 2026.
• Business Quant data shows BDTX's Assets Average at $138.0 million in Q1 2026, $150.4 million in Q4 2025, and $162.1 million in Q3 2025.